Develops biologics for immuno-oncology and autoimmune diseases, focusing on innovative approaches to enhance therapeutic outcomes.
I-Mab, headquartered in Shanghai, China, is an innovative clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing biologics for the treatment of cancer and autoimmune disorders. The company's robust pipeline includes several promising candidates at various stages of clinical development. Among its lead products is Felzartamab, a CD38 antibody currently in Phase 1b/2a trials for membranous nephropathy. Additionally, I-Mab is advancing Eftansomatropin alfa, a long-acting human growth hormone that has completed Phase 3 trials for pediatric growth hormone deficiency.
I-Mab's portfolio also features TJ107, a recombinant human IL-7 in Phase 2 trials for cancer treatment-related lymphopenia and immunotherapy, and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 trials. Other notable candidates include Enoblituzumab, a Phase 2 humanized B7-H3 antibody for treating head and neck cancer, and Efineptakin, a long-acting IL-7 in Phase 2 for lymphopenia and cancer immunotherapy. The company is also advancing TJ210, a Phase 1 monoclonal antibody targeting human C5aR1 for cancers and autoimmune diseases.
Founded in 2014, I-Mab has established strategic collaborations with industry leaders such as AbbVie, Sinopharm Group, PT Kalbe Genexine Biologics, and Roche Diagnostics, bolstering its capabilities in biopharmaceutical research and development. With a mission to address critical medical needs through cutting-edge biologic therapies, I-Mab continues to expand its global footprint and advance towards delivering innovative treatments that improve patient outcomes worldwide.